|
|
 Chang
H. Ahn, Ph.D., Chairman
|
|
Charles
Beever, MBA, Director
|
|
Kwang
Soo Cheong, Ph.D., Director
|
|
Y.
Michelle Kang, Director
|
|
David
M. McIntosh, J.D., Director
|
|
Tae
Heum (Ted) Jeong, M.S., Secretary
|
|
Freddie
Ann Hoffman, M.D., Director
|
Chang
H. Ahn.
Dr. Chang H. Ahn is an internationally recognized
drug development expert with over 20 years of experience
in the fields of pharmacology and biotechnology. He
founded Rexahn in 2001, and currently serves as the
company¡¯s Chairman and Chief Executive Officer. Prior,
Dr. Ahn held dual positions as both Expert Regulatory
Officer and Laboratory Chief at the FDA¡¯s Center for
Drug Evaluation and Research. While at the FDA,
Dr. Ahn represented the agency in the fields of Antisense
Oligonucleotide Therapeutics and Multi-Drug Resistance,
and served a key role as both author and co-author of
several FDA guidance documents. Before joining
the FDA, Dr. Ahn carried out cancer research at the
National Cancer Institute and Emory University¡¯s School
of Medicine. Dr. Ahn organized and chaired the
U.S.-Korea Bio Business and Partnership Forum, of which
Maryland State and Montgomery County are partners. He
has also served as president of the Society of Biomedical
Research since 2000. He was named as ¡°Maryland¡¯s
25 CEOs You Need to Know¡± in 2006 by Gazette News and
Rexahn was honored ¡°2006 Biotechnology Company of the
Year¡± in 2007 by the Monte Jade Science and Technology
Association. Dr. Ahn earned his Ph.D. in pharmacology
at Ohio State University in 1985. He also holds
two B.S. degrees in pharmacy from Creighton University
and Seoul National University, Seoul, Korea 
Charles
Beever.
Mr. Beever has served as a director since May
2006. He has been a partner and Vice President
of Booz Allen & Hamilton, Inc. since October 1993,
and served as staff member and Engagement Manager at
Booz Allen Hamilton from January 1984 to October 2003.
Prior to joining Booz Allen Hamilton, Mr. Beever
served as Plant Production Manager from October 1981
to January 1984, Industrial Engineering Manager from
June 1979 to October 1981 and Production Supervisor
from July 1978 to June 1979 at McGraw-Edison Company.
Mr. Beever holds a B.A. in Economics from Haverford
College, where he was elected to Phi Beta Kappa, and
an M.B.A. from the Harvard Graduate School of Business
Administration.
Kwang
Soo Cheong.
Dr. Cheong has served as a director since May
2006. He is a faculty member at the Department
of Finance of the Johns Hopkins University Carey Business
School (Assistant Professor: 2001-2005 & Associate
Professor: 2006 to date). Dr. Cheong was an Assistant
Professor of Economics at the University of Hawaii from
1994 to 2001, and he was a lecturer at the Department
of Economics of Stanford University from 1993 to 1994.
During the summer of 1995, Dr. Cheong was a Visiting
Fellow in the Taxation and Welfare Division at the Korea
Development Institute in Korea.Dr. Cheong holds a B.A.
in Economics and an M.A. in Economics from Seoul National
University, and a Ph.D. in Economics from Stanford University.
Y.
Michele Kang.
Ms. Kang has served as a director since May
2006. She has been Vice President and General
Manager of Northrop Grumman Information Technology's
Health Solutions division since 2003; Vice President
and Deputy General Manager, Global Information Technology
of Northrop Grumman Mission Systems from 2001 to 2003;
and Vice President, e-Business of Northrop Grumman Mission
Systems from 2000 to 2001. She is a member of
the eHealth Initiative Leadership Council and a member
of the steering committee of Connecting for Health.
Prior to joining Northrop Grumman, Ms. Kang was
a partner in the Strategic Advisory Services group of
Ernst & Young LLP. Ms. Kang received a B.A.
in Economics from the University of Chicago and a Master's
degree in Public and Private Management from the Yale
School of Management.
David
McIntosh.
Mr. McIntosh has served as a director since May
2005. Mr. McIntosh served as a director of Rexahn,
Corp from March 2004 to May 2005. He has been a partner
at Mayer, Brown, Rowe & Maw LLP (law firm) since
2001. Mr. McIntosh was a member of the United States
House of Representatives, representing the 2nd District
of Indiana from 1995 to 2001. From 1993 to 1994,
he was a director of the Hudson Institute Competitiveness
Center. He served on President Bush's Council
on Competitiveness as Executive Director from 1989 to
1993. He also served as the Special Assistant
to President Reagan for Domestic Affairs from 1987 to
1989 and was the Special Assistant to the Attorney General
of the United States from 1986 to 1987. Mr. McIntosh
received a B.A. from Yale College and a J.D. from the
University of Chicago Law School.
Tae
Heum (Ted) Jeong.
Ted Jeong joined Rexahn Pharmaceuticals in 2002 and has extensive experience as a venture capitalist. Prior to joining Rexahn, Mr. Jeong spent six years as a senior investment manager at Hyundai Venture Investment Corporation, the leading Korean venture capital firm. While there, he managed the biotech investment team, invested in over 50 venture companies and produced successful returns on over 15 investment projects. Mr. Jeong operated two specialized biotechnology funds and fundraised a total of $50 million. He also held the position of Committee Member with the Industrial Development Fund of the Korean Ministry of Commerce, Industry and Energy. After joining Rexahn, Mr. Jeong¡¯s accomplishments include securing public market listings, mergers, and successful fundraising efforts. He arranged and executed public listing for Rexahn on the NASDAQ OTCBB in 2005, and then on the AMEX in 2008. He also succeeded in obtaining $30 million in equity funding for the Company. Mr. Jeong holds a M.S. in Finance from Johns Hopkins University, a B.S. in Chemistry and an M.S., specializing in Biomedical Chemistry, from POSTECH, Pohang, Korea.
Freddie
Ann Hoffman.
Dr. Hoffman has served as a director since June 2007.
Dr. Hoffman is CEO of HeteroGeneity, LLC,
a Washington-DC based consulting firm, which she founded
in 2003. She served as Senior Medical Director
for New Product Development for Pfizer Consumer Healthcare
from 1999 to 2003. From 1986 until 1999,
Dr. Hoffman served as Chief of the Cytokines, Growth
Factors and Oncologic Products Branch, in the FDA Center
for Biologics Evaluation and Review, where she was involved
with the licensing of 15 biologic drugs. While
at FDA she also served as deputy director of the Medicine
Branch, within the Office of the FDA Commissioner. Before
joining FDA, Dr. Hoffman completed a fellowship in pediatric
hematology-oncology at the National Cancer Institute,
where she spent a decade conducting clinical and laboratory
research, and serving as Director of Extramural Clinical
Trials in the Biological Response Modifiers Branch,
NCI. She has a Bachelors of Science in Chemistry
from UCLA, and a Medical Degree and general pediatric
residency training from the University of California
at Davis.
|
